丹参根中活性化合物均具有较强的药理活性。MYB转录因子则是活性化合物生物合成途径中的重要调控因子。我们前期研究表明MYB很可能参与调控了丹参活性化合物的生物合成。本项目将在此基础上，拟通过基因过表达和RNA干扰的方法研究SmMYB3、SmMYB6和SmMYB109转录因子在活性化合物积累中的作用；比较分析转基因和非转基因丹参中活性化合物化合物的组分和含量；高通量分析转基因植株转录组的变化，找出差异表达的基因；采用CHIP-seq在全基因组范围内分析MYB转录因子的靶位点。RNA-seq和CHIP-seq联合分析SmMYBs所调控的差异基因，构建丹参活性化合物合成的调控网络，为彻底揭示丹参活性化合物生物合成的遗传控制机制，利用基因工程手段获得药用活性成分含量较高的丹参新品系，及利用合成生物学技术合成相关的药用活性成分奠定基础。

The main bioactive components of S. miltiorrhiza include the water-soluble (hydrophilic) phenolics and the lipid-soluble tanshinones, and they have strong pharmacological activity. MYB transcription factor is involved in the biosynthesis of bioactive compounds. But now, research on MYB transcription factor regulating the biosynthesis of the bioactive compound is still in its infancy. Our previous studies have shown that MYB probably be involved in the regulation of the biosynthesis of the bioactive compounds. We intend to study the function of SmMYB3, SmMYB6 and SmMYB109 in the accumulation of the bioactive compounds by gene overexpression and RNA interference; compare and analyse components and contents of the bioactive compounds in transgenic and non-transgenic plants; identify differentially expressed genes by high throughput analyses. ChIP-Seq analysis will detect MYB DNA binding sites in the scope of the genome. Overlay of the RNA-Seq and ChIP-Seq results will reveal MYB-modulated target genes. The transcriptional regulatory framework of MYB will be build. The regulatory framework provides foundation for completely reveal the genetic control mechanism of the bioactive compounds.